Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04471727
Title A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Acronym MK-6070-001/HPN328-4001
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute RECRUITING Los Angeles California 90048 United States Details
University of California San Francisco RECRUITING San Francisco California 94143 United States Details
University of Colorado RECRUITING Aurora Colorado 80045 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02467 United States Details
Karmanos Cancer Center RECRUITING Detroit Michigan 48201 United States Details
Roswell Park Comprehensive Cancer Center RECRUITING Buffalo New York 14263 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10021 United States Details
University Hospitals Cleveland Medical Center RECRUITING Cleveland Ohio 44106 United States Details
Providence RECRUITING Portland Oregon 97213 United States Details
Tennessee Oncology RECRUITING Nashville Tennessee 37203 United States Details
Medical College of Wisconsin RECRUITING Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field